Skip to content

Edwards Lifesciences

US · EW #442 by market cap Listed 1970
101.85 -2.03 -1.95%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 103.21 -0.64%
After-hours 101.85 0.00%
107.1582.63101.852026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on EW?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +17.3% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Analyst tilt is Buy.
Quant Technical Outlook Bullish
  • Price is above its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days C → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 6 of 6 factors. Missing data is not a zero score.

Overall B+
ValuationGrowthProfitMomentumHealthAnalyst
Valuation F

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 57.5x Better than 8%
Forward P/E 32.3x Better than 16%
Price / Sales 8.8x Better than 12%
P/E vs own 5-yr range 99th pctl Better than 3%
Growth B-

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 10.8% Better than 66%
Net income CAGR (3Y) -11.0% Better than 26%
Free cash flow CAGR (3Y) 11.9% Better than 55%
Profitability A-

How much profit the business keeps from each dollar of sales and capital.

Gross margin 78.0% Better than 89%
Operating margin 27.0% Better than 87%
Net margin 17.7% Better than 76%
Return on equity 10.6% Better than 54%
Return on invested capital 8.7% Better than 63%
Momentum A

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 13.4% Better than 93%
6-month return 18.7% Better than 82%
12-month return (ex latest month) 4.6% Better than 40%
Distance below 52-week high 5.7% Better than 93%
Financial Health A

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 3.7x Better than 79%
Debt to assets 5.1% Better than 79%
Interest coverage 63.4x Better than 91%
Free cash flow / net income 124.4% Better than 54%
Analyst View B-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 95.2% Better than 77%
Upside to average target 13.9% Better than 20%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -4.95%
1M +15.36%
3M +13.38%
6M +22.76%
YTD +19.47%
1Y +21.12%
3Y +51.59%
5Y -12.97%

Key statistics

Price & volume

Prev close
103.88
Open
104.48
Day range
101.65 - 104.96
Avg price
102.57
Volume
3.62M
Turnover
371.41M
Amplitude
3.19%
52-week range
74.66 - 108.00

Valuation

P/E
55.66
P/E (TTM)
57.54
P/B
5.39
EPS
1.83
Net profit
1.05B
Net assets
10.86B

Share structure

Market cap
58.56B
Float cap
58.38B
Shares out
575.00M
Float shares
573.23M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 82% of range
74.66 108.00

5.7% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-5.70M net over the window

Short interest

Shares short
9.38M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Edwards Lifesciences (EW)?

Edwards Lifesciences last traded at 101.85. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Edwards Lifesciences's market cap?

About 58.56B.

What is the P/E ratio of Edwards Lifesciences?

The trailing twelve-month P/E is 57.54, above its own 5-year average of 33.42 — toward the top of its historical range (99.20% percentile). See the Valuation tab for the full history.

Does Edwards Lifesciences pay a dividend?

Edwards Lifesciences does not currently pay a regular dividend.

Is Edwards Lifesciences a buy according to analysts?

The consensus of 21 analysts is a Buy rating, with an average 12-month price target of 116.05, which implies 13.9% upside from the current price. This is not investment advice.

What is Edwards Lifesciences's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Edwards Lifesciences a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 20:02:29 · For reference only, not investment advice and not tailored to your situation.

Edwards Lifesciences discussion 0 comments

Add a comment